Heartland Bank & Trust Co Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Heartland Bank & Trust Co lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.6% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 608 shares of the biopharmaceutical company’s stock after selling 16 shares during the quarter. Heartland Bank & Trust Co’s holdings in Regeneron Pharmaceuticals were worth $639,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. SteelPeak Wealth LLC raised its holdings in Regeneron Pharmaceuticals by 173.0% during the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock valued at $1,148,000 after buying an additional 692 shares during the period. Atria Investments Inc increased its stake in Regeneron Pharmaceuticals by 12.2% in the first quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock worth $8,317,000 after purchasing an additional 941 shares during the period. Tri Locum Partners LP increased its stake in Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock worth $18,410,000 after purchasing an additional 8,949 shares during the period. Nordea Investment Management AB increased its stake in Regeneron Pharmaceuticals by 23.2% in the first quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock worth $28,218,000 after purchasing an additional 5,495 shares during the period. Finally, Tidal Investments LLC increased its stake in Regeneron Pharmaceuticals by 16.8% in the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after purchasing an additional 711 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 2.2 %

Shares of NASDAQ:REGN opened at $941.39 on Thursday. The business has a 50-day moving average price of $1,098.29 and a 200-day moving average price of $1,040.67. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The stock has a market cap of $103.73 billion, a price-to-earnings ratio of 27.81, a PEG ratio of 3.40 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. Regeneron Pharmaceuticals’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period last year, the business earned $8.79 earnings per share. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.6 EPS for the current year.

Analysts Set New Price Targets

REGN has been the topic of a number of recent analyst reports. Morgan Stanley reduced their target price on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Royal Bank of Canada reissued an “outperform” rating and set a $1,260.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday. Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday. JPMorgan Chase & Co. increased their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Finally, Piper Sandler increased their price target on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a research report on Friday, August 23rd. One analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,102.19.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now directly owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares in the company, valued at $4,498,280. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.